Follow all the latest from Fresenius Kabi biosimilars
Latest News
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi with an intravenous and subcutaneous formulation approved by the FDA. The tocilizumab biosimilar provides increased access and an affordable, high-quality, and safe treatment option for U.S. patients.
Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and Subcutaneous tocilizumab biosimilar approved by the FDA
Tyenne® provides a comprehensive, accessible, and high-quality treatment option for U.S. patients treated with tocilizumab.
IDACIO® (adalimumab-aacf) Now Available in the United States
Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab).
Upcoming Events
HCP
October 23-25, 2023
Connect with us in St. Louis at the Fall Hospital Pharmacy Conference.
Chicago Race for the Cure
October 28, 2023
Connect with us in Chicago’s Soldier Field for the Susan G. Komen Race for the Cure.
ASHP Mid-Year
December 3-7, 2023
Connect with us in Anaheim at the American Society of Health-System Pharmacists Mid-year Meeting.
AIBD
December 14-16, 2023
See us in Orlando at the Advances in Inflammatory Bowel Diseases Conference.
Resources
- All Resources
- Guides
- Useful Links
- Videos
- Webinars
